Disease Modifying Treatment Special Authority Criteria

New Special Authority criteria

From 1 March 2021, funded access to the eight funded MS treatments will be amended in Section B (the Community) of the Pharmaceutical Schedule. Equivalent changes will also be made in Part II of Section H (the Hospital Medicines List) of the Pharmaceutical Schedule. The new criteria will be:

Special Authority for Subsidy

Initial application – (Multiple sclerosis) from a neurologist or general physician.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier. Treatment on two funded multiple sclerosis treatments simultaneously is not permitted.

Renewal– (Multiple sclerosis) only from a neurologist or general physician.  Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) at any time in the last six months (i.e. the patient has walked 100 metres or more with or without aids in the last six months).

For more information visit the PHARMAC website


Stem Cell Transplant
Managing and Treating MS

Stem cell therapy is any treatment that uses or targets stem cells

Understanding MS

Primary symptoms of MS